{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T12:50:30Z","timestamp":1791204630038,"version":"4.2.0"},"reference-count":68,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2014,9,1]],"date-time":"2014-09-01T00:00:00Z","timestamp":1409529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,9,1]],"date-time":"2014-09-01T00:00:00Z","timestamp":1409529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal.chestnet.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Chest"],"published-print":{"date-parts":[[2014,9]]},"DOI":"10.1378\/chest.13-2634","type":"journal-article","created":{"date-parts":[[2014,3,13]],"date-time":"2014-03-13T09:31:16Z","timestamp":1394703076000},"page":"686-708","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":44,"title":["Effect of Pulmonary Arterial Hypertension-Specific Therapies on Health-Related Quality of Life"],"prefix":"10.1016","volume":"146","author":[{"given":"Gilles","family":"Rival","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yves","family":"Lacasse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvie","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e9bastien","family":"Bonnet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steeve","family":"Provencher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1378\/chest.13-2634_bib1","doi-asserted-by":"crossref","first-page":"343","DOI":"10.7326\/0003-4819-115-5-343","article-title":"Survival in patients with primary pulmonary hypertension. Results from a national prospective registry","volume":"115","author":"D'Alonzo","year":"1991","journal-title":"Ann Intern Med"},{"issue":"suppl 1","key":"10.1378\/chest.13-2634_bib2","doi-asserted-by":"crossref","first-page":"S43","DOI":"10.1016\/j.jacc.2009.04.012","article-title":"Updated clinical classification of pulmonary hypertension","volume":"54","author":"Simonneau","year":"2009","journal-title":"J Am Coll Cardiol"},{"issue":"14","key":"10.1378\/chest.13-2634_bib3","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1056\/NEJMra040291","article-title":"Treatment of pulmonary arterial hypertension","volume":"351","author":"Humbert","year":"2004","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1378\/chest.13-2634_bib4","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1093\/eurheartj\/ehp022","article-title":"A meta-analysis of randomized controlled trials in pulmonary arterial hypertension","volume":"30","author":"Gali\u00e8","year":"2009","journal-title":"Eur Heart J"},{"issue":"5","key":"10.1378\/chest.13-2634_bib5","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1093\/eurheartj\/ehi728","article-title":"Long-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension","volume":"27","author":"Provencher","year":"2006","journal-title":"Eur Heart J"},{"issue":"4","key":"10.1378\/chest.13-2634_bib6","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/S0735-1097(02)02012-0","article-title":"Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival","volume":"40","author":"Sitbon","year":"2002","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"10.1378\/chest.13-2634_bib7","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1161\/01.CIR.0000029100.82385.58","article-title":"Survival in primary pulmonary hypertension: the impact of epoprostenol therapy","volume":"106","author":"McLaughlin","year":"2002","journal-title":"Circulation"},{"issue":"2","key":"10.1378\/chest.13-2634_bib8","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1183\/09031936.05.00054804","article-title":"Survival with first-line bosentan in patients with primary pulmonary hypertension","volume":"25","author":"McLaughlin","year":"2005","journal-title":"Eur Respir J"},{"issue":"2","key":"10.1378\/chest.13-2634_bib9","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1161\/CIRCULATIONAHA.109.911818","article-title":"Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era","volume":"122","author":"Humbert","year":"2010","journal-title":"Circulation"},{"issue":"1","key":"10.1378\/chest.13-2634_bib10","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1038\/clpt.1981.18","article-title":"Clinical biostatistics. LIV. The biostatistics of concordance","volume":"29","author":"Kramer","year":"1981","journal-title":"Clin Pharmacol Ther"},{"key":"10.1378\/chest.13-2634_bib11","article-title":"Cochrane Handbook for Systematic Reviews of Interventions,Version 5.1.0. Updated March 2011","author":"Higgins","year":"2011","journal-title":"London, England: The Cochrane Collaboration"},{"issue":"1","key":"10.1378\/chest.13-2634_bib12","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/0895-4356(94)00097-A","article-title":"Best evidence synthesis: an intelligent alternative to meta-analysis","volume":"48","author":"Slavin","year":"1995","journal-title":"J Clin Epidemiol"},{"issue":"5","key":"10.1378\/chest.13-2634_bib13","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1056\/NEJM199602013340504","article-title":"Primary Pulmonary Hypertension Study Group. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension","volume":"334","author":"Barst","year":"1996","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1378\/chest.13-2634_bib14","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1056\/NEJMoa020204","article-title":"Aerosolized Iloprost Randomized Study Group. Inhaled iloprost for severe pulmonary hypertension","volume":"347","author":"Olschewski","year":"2002","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1378\/chest.13-2634_bib15","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1164\/ajrccm.165.6.2106079","article-title":"Treprostinil Study Group. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial","volume":"165","author":"Simonneau","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"issue":"12","key":"10.1378\/chest.13-2634_bib16","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1016\/S0735-1097(03)00463-7","article-title":"Beraprost Study Group. Beraprost therapy for pulmonary arterial hypertension","volume":"41","author":"Barst","year":"2003","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"10.1378\/chest.13-2634_bib17","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/j.jacc.2003.10.056","article-title":"Clinical efficacy of sildenafil in primary pulmonary hypertension: a randomized, placebo-controlled, double-blind, crossover study","volume":"43","author":"Sastry","year":"2004","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"10.1378\/chest.13-2634_bib18","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1378\/chest.126.2.420","article-title":"Treprostinil Study Group. Treprostinil, a prostacyclin analogue, in pulmonary arterial hypertension associated with connective tissue disease","volume":"126","author":"Oudiz","year":"2004","journal-title":"Chest"},{"issue":"4","key":"10.1378\/chest.13-2634_bib19","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1164\/rccm.200307-957OC","article-title":"STRIDE-1 Study Group. Sitaxsentan therapy for pulmonary arterial hypertension","volume":"169","author":"Barst","year":"2004","journal-title":"Am J Respir Crit Care Med"},{"issue":"11","key":"10.1378\/chest.13-2634_bib20","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1136\/ard.2007.069609","article-title":"Selective endothelin A receptor antagonism with sitaxsentan for pulmonary arterial hypertension associated with connective tissue disease","volume":"66","author":"Girgis","year":"2007","journal-title":"Ann Rheum Dis"},{"issue":"23","key":"10.1378\/chest.13-2634_bib21","doi-asserted-by":"crossref","first-page":"3010","DOI":"10.1161\/CIRCULATIONAHA.107.742510","volume":"117","author":"Gali\u00e8","year":"2008","journal-title":"Circulation"},{"issue":"8","key":"10.1378\/chest.13-2634_bib22","doi-asserted-by":"crossref","first-page":"521","DOI":"10.7326\/0003-4819-149-8-200810210-00004","article-title":"PACES Study Group. Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial","volume":"149","author":"Simonneau","year":"2008","journal-title":"Ann Intern Med"},{"issue":"1","key":"10.1378\/chest.13-2634_bib23","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1378\/chest.07-0592","article-title":"Sildenafil improves health-related quality of life in patients with pulmonary arterial hypertension","volume":"133","author":"Pepke-Zaba","year":"2008","journal-title":"Chest"},{"issue":"9630","key":"10.1378\/chest.13-2634_bib24","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1016\/S0140-6736(08)60919-8","article-title":"Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial","volume":"371","author":"Gali\u00e8","year":"2008","journal-title":"Lancet"},{"issue":"10","key":"10.1378\/chest.13-2634_bib25","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1185\/03007990903210066","article-title":"Tadalafil therapy and health-related quality of life in pulmonary arterial hypertension","volume":"25","author":"Pepke-Zaba","year":"2009","journal-title":"Curr Med Res Opin"},{"issue":"18","key":"10.1378\/chest.13-2634_bib26","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/j.jacc.2010.01.027","article-title":"Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial","volume":"55","author":"McLaughlin","year":"2010","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1378\/chest.13-2634_bib27","first-page":"A5887","article-title":"The effect of sitaxentan on exercise capacity, hemodynamic function, and health-related quality of life in adults with pulmonary arterial hypertension associated with connective tissue disease [abstract]","volume":"183","author":"Mychaskiw","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1378\/chest.13-2634_bib28","first-page":"A3269","article-title":"Macitentan improves health-related quality of life in pulmonary arterial hypertension: results from the randomized controlled SERAPHIN trial [abstract]","volume":"187","author":"Mehta","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"10.1378\/chest.13-2634_bib29","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1056\/NEJMoa1209655","article-title":"PATENT-1 Study Group. Riociguat for the treatment of pulmonary arterial hypertension","volume":"369","author":"Ghofrani","year":"2013","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1378\/chest.13-2634_bib30","first-page":"2894","article-title":"Pulmonary Arterial Hypertension and Response to Tadalafil (PHIRST) Study Group. Tadalafil therapy for pulmonary arterial hypertension [published correction appears in .Circulation. 2011;124(10):e279]","volume":"119","author":"Gali\u00e8","year":"2009","journal-title":"Circulation"},{"issue":"20","key":"10.1378\/chest.13-2634_bib31","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1056\/NEJMoa050010","article-title":"Sildenafil Use in Pulmonary Arterial Hypertension (SUPER) Study Group. Sildenafil citrate therapy for pulmonary arterial hypertension","volume":"353","author":"Gali\u00e8","year":"2005","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1378\/chest.13-2634_bib32","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1213917","article-title":"SERAPHIN Investigators. Macitentan and morbidity and mortality in pulmonary arterial hypertension","volume":"369","author":"Pulido","year":"2013","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1378\/chest.13-2634_bib33","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/BF02602348","article-title":"Development and testing of a new measure of health status for clinical trials in heart failure","volume":"4","author":"Guyatt","year":"1989","journal-title":"J Gen Intern Med"},{"issue":"4","key":"10.1378\/chest.13-2634_bib34","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/0197-2456(89)90005-6","article-title":"Measurement of health status. Ascertaining the minimal clinically important difference","volume":"10","author":"Jaeschke","year":"1989","journal-title":"Control Clin Trials"},{"issue":"273","key":"10.1378\/chest.13-2634_bib35","first-page":"185","article-title":"Measuring health status: a new tool for clinicians and epidemiologists","volume":"35","author":"Hunt","year":"1985","journal-title":"J R Coll Gen Pract"},{"key":"10.1378\/chest.13-2634_bib37","first-page":"198","article-title":"Patients self-assessment of their congestive heart failure: content, reliability and validity of a new measure: the Minnesota Living With Heart Failure Questionnaire","volume":"3","author":"Rector","year":"1987","journal-title":"Heart Fail"},{"issue":"10","key":"10.1378\/chest.13-2634_bib39","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1007\/s00586-005-0898-2","article-title":"Health-related quality of life assessment by the EuroQol-5D can provide cost-utility data in the field of low-back surgery","volume":"14","author":"Solberg","year":"2005","journal-title":"Eur Spine J"},{"issue":"3","key":"10.1378\/chest.13-2634_bib40","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/0168-8510(90)90421-9","volume":"16","year":"1990","journal-title":"Health Policy"},{"issue":"11","key":"10.1378\/chest.13-2634_bib41","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1097\/00005650-199711000-00002","article-title":"Modeling valuations for EuroQol health states","volume":"35","author":"Dolan","year":"1997","journal-title":"Med Care"},{"issue":"11","key":"10.1378\/chest.13-2634_bib42","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1016\/S0895-4356(98)00109-7","article-title":"Cross-validation of item selection and scoring for the SF-12 Health Survey in nine countries: results from the IQOLA Project. International Quality of Life Assessment","volume":"51","author":"Gandek","year":"1998","journal-title":"J Clin Epidemiol"},{"issue":"6","key":"10.1378\/chest.13-2634_bib43","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/00005650-199206000-00002","article-title":"The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection","volume":"30","author":"Ware","year":"1992","journal-title":"Med Care"},{"issue":"6","key":"10.1378\/chest.13-2634_bib44","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1093\/rheumatology\/kem069","article-title":"Improvement in patient-reported outcomes for patients with ankylosing spondylitis treated with etanercept 50 mg once-weekly and 25 mg twice-weekly","volume":"46","author":"Braun","year":"2007","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"10.1378\/chest.13-2634_bib45","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1378\/chest.07-0275","article-title":"Estimating a minimally important difference in pulmonary arterial hypertension following treatment with sildenafil","volume":"135","author":"Gilbert","year":"2009","journal-title":"Chest"},{"issue":"1","key":"10.1378\/chest.13-2634_bib46","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1186\/1477-7525-11-161","article-title":"Development and validation of the living with pulmonary hypertension questionnaire in pulmonary arterial hypertension patients","volume":"11","author":"Bonner","year":"2013","journal-title":"Health Qual Life Outcomes"},{"issue":"4","key":"10.1378\/chest.13-2634_bib47","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1183\/09031936.06.00130405","article-title":"Measurement of quality of life in pulmonary hypertension and its significance","volume":"28","author":"Cenedese","year":"2006","journal-title":"Eur Respir J"},{"issue":"1","key":"10.1378\/chest.13-2634_bib48","first-page":"A3534","article-title":"Efficacy Of riociguat in pretreated versus treatment-na\u00efve patients with pulmonary arterial hypertension (PAH) in the phase III PATENT-1 study [abstract]","volume":"187","author":"Humbert","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"10.1378\/chest.13-2634_bib49","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1513\/pats.200802-020SK","article-title":"Health-related quality of life and patient-reported outcomes in pulmonary arterial hypertension","volume":"5","author":"Chen","year":"2008","journal-title":"Proc Am Thorac Soc"},{"key":"10.1378\/chest.13-2634_bib50","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/1465-9921-6-92","article-title":"Health-related quality of life in patients with pulmonary arterial hypertension","volume":"6","author":"Taichman","year":"2005","journal-title":"Respir Res"},{"issue":"11","key":"10.1378\/chest.13-2634_bib51","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1111\/j.1445-5994.2006.01169.x","article-title":"Comparison and validation of three measures of quality of life in patients with pulmonary hypertension","volume":"36","author":"Chua","year":"2006","journal-title":"Intern Med J"},{"issue":"4","key":"10.1378\/chest.13-2634_bib52","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s00408-013-9472-6","article-title":"Exercise capacity affects quality of life in patients with pulmonary hypertension","volume":"191","author":"Halank","year":"2013","journal-title":"Lung"},{"issue":"2","key":"10.1378\/chest.13-2634_bib53","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1378\/chest.12-2443","article-title":"Patient-reported outcomes assessed by the CAMPHOR questionnaire predict clinical deterioration in idiopathic pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension","volume":"144","author":"McCabe","year":"2013","journal-title":"Chest"},{"issue":"10","key":"10.1378\/chest.13-2634_bib54","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1016\/j.rmed.2008.04.016","article-title":"Evaluation of disease-specific health-related quality of life in patients with pulmonary arterial hypertension","volume":"102","author":"Zlupko","year":"2008","journal-title":"Respir Med"},{"issue":"5","key":"10.1378\/chest.13-2634_bib55","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1378\/chest.126.5.1452","article-title":"Health-related quality of life in patients with pulmonary arterial hypertension","volume":"126","author":"Shafazand","year":"2004","journal-title":"Chest"},{"issue":"2","key":"10.1378\/chest.13-2634_bib56","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1111\/j.1475-6773.2005.0l374.x","article-title":"A comparison of clinically important differences in health-related quality of life for patients with chronic lung disease, asthma, or heart disease","volume":"40","author":"Wyrwich","year":"2005","journal-title":"Health Serv Res"},{"issue":"1","key":"10.1378\/chest.13-2634_bib57","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s11136-005-3513-4","article-title":"The Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR): a measure of health-related quality of life and quality of life for patients with pulmonary hypertension","volume":"15","author":"McKenna","year":"2006","journal-title":"Qual Life Res"},{"issue":"suppl 1","key":"10.1378\/chest.13-2634_bib58","doi-asserted-by":"crossref","first-page":"S97","DOI":"10.1016\/j.jacc.2009.04.007","article-title":"End points and clinical trial design in pulmonary arterial hypertension","volume":"54","author":"McLaughlin","year":"2009","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"10.1378\/chest.13-2634_bib59","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1016\/j.jacc.2006.01.057","article-title":"STRIDE-2 Study Group. Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan","volume":"47","author":"Barst","year":"2006","journal-title":"J Am Coll Cardiol"},{"issue":"9288","key":"10.1378\/chest.13-2634_bib60","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/S0140-6736(01)06250-X","article-title":"Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study","volume":"358","author":"Channick","year":"2001","journal-title":"Lancet"},{"issue":"12","key":"10.1378\/chest.13-2634_bib61","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJMoa012212","article-title":"Bosentan therapy for pulmonary arterial hypertension","volume":"346","author":"Rubin","year":"2002","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1378\/chest.13-2634_bib62","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1161\/CIRCULATIONAHA.106.630715","article-title":"Bosentan Randomized Trial of Endothelin Antagonist Therapy-5 (BREATHE-5) Investigators. Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study","volume":"114","author":"Gali\u00e8","year":"2006","journal-title":"Circulation"},{"issue":"6","key":"10.1378\/chest.13-2634_bib63","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1378\/chest.11-2212","article-title":"Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and\/or phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C study): a randomized controlled trial","volume":"142","author":"Tapson","year":"2012","journal-title":"Chest"},{"issue":"5","key":"10.1378\/chest.13-2634_bib64","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1161\/CIRCULATIONAHA.112.124388","article-title":"Efficacy and safety of oral treprostinil monotherapy for the treatment of pulmonary arterial hypertension: a randomized, controlled trial","volume":"127","author":"Jing","year":"2013","journal-title":"Circulation"},{"issue":"10","key":"10.1378\/chest.13-2634_bib65","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1161\/CIRCULATIONAHA.112.000765","article-title":"Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: results of the randomized IMPRES study","volume":"127","author":"Hoeper","year":"2013","journal-title":"Circulation"},{"issue":"3","key":"10.1378\/chest.13-2634_bib66","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1183\/09031936.04.00028404","article-title":"Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2","volume":"24","author":"Humbert","year":"2004","journal-title":"Eur Respir J"},{"issue":"11","key":"10.1378\/chest.13-2634_bib67","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1164\/rccm.200603-358OC","article-title":"Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension","volume":"174","author":"McLaughlin","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"issue":"9","key":"10.1378\/chest.13-2634_bib68","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1093\/eurheartj\/ehq011","article-title":"Combination therapy with bosentan and sildenafil in Eisenmenger syndrome: a randomized, placebo-controlled, double-blinded trial","volume":"31","author":"Iversen","year":"2010","journal-title":"Eur Heart J"},{"issue":"4","key":"10.1378\/chest.13-2634_bib69","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1183\/09031936.00137511","article-title":"Selexipag: an oral, selective prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension","volume":"40","author":"Simonneau","year":"2012","journal-title":"Eur Respir J"},{"issue":"6","key":"10.1378\/chest.13-2634_bib70","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1007\/s11136-012-0252-1","article-title":"Patient-reported outcomes in randomized clinical trials: development of ISOQOL reporting standards","volume":"22","author":"Brundage","year":"2013","journal-title":"Qual Life Res"}],"container-title":["Chest"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369215510763?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369215510763?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T07:23:39Z","timestamp":1757921019000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0012369215510763"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9]]},"references-count":68,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,9]]}},"alternative-id":["S0012369215510763"],"URL":"https:\/\/doi.org\/10.1378\/chest.13-2634","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.718310820.793501135","asserted-by":"object"}]},"ISSN":["0012-3692"],"issn-type":[{"value":"0012-3692","type":"print"}],"subject":[],"published":{"date-parts":[[2014,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of Pulmonary Arterial Hypertension-Specific Therapies on Health-Related Quality of Life","name":"articletitle","label":"Article Title"},{"value":"Chest","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1378\/chest.13-2634","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 The American College of Chest Physicians. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}